One criticism i had of this company when I looked into it some months ago was the inadequate agreements it had signed with Transgene - didn't give me a lot of faith in the management that had given so much away for little money. These types of issues I believe contributed to VHL's failures previously.
The GGTI agreements - better, but still not that impressive. Initially I thought that VHL was simply incapable of negotiating fair agreements no matter which side of the negotiation table their sitting on. After reading the pres, and the previous announcements on GGTI, these agreements are a step in the right direction. Hopefully as a result of the new additions to the management team.
"Currently undertaking a review commercial opportunities for Co-X-Gene". Straight from the presso.
This could be the catalyst - if management can show that they are able to negotiate a fairer agreement (license, sub-license or painshare/gainshare model) for Co xGene, then investors may start showing some trust. And respect.
VHL Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
